## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	 of	2

ripproved for and mind	70B11 00.0 11 00 00;	01.12 0031-0031
Application Number	10/764,676	
Filing Date	January 26, 2	004011
First Named Inventor	Peter Rohner	
Art Unit	1615	JUL 0 2 2004
Examiner Name		
Attorney Docket Number	13183 0037	1/2

U.S. PATENT DOCUMENTS					
Examiner Cite		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines Where Relevant
Initials* No.1	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear
40		US-2002/0177558 A1	11-28-2002	Meyerhoff et al.	
	_	US-			
_ "		US-			
		US-			•
		US-			
		US-			

FOREIGN PATENT DOCUMENTS					
C'a.	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines	
miner Cite als* No. 1 Country Code <sup>3</sup> Number*Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	т <sup>6</sup>	
	WO 02/096398 A2	12-05-2002	Esparma GmbH et al.		
	WO 02/096414 A1	12-05-2002	Serumwerk Bernburg AG	•	
_					
	Cite No. 1	Cite No. 1 Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)  WO 02/096398 A2	Cite No. 1 Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)  WO 02/096398 A2 12-05-2002	Cite No. 1 Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) Date MM-DD-YYYY Proceed and the control of Cited Document  WO 02/096398 A2 12-05-2002 Esparma GmbH et al.  WO 02/096414 A1 12-05-2002 Serumwerk	Cite No. 1 Country Code <sup>3</sup> Number Kind Code (if known) Publication Date MM-DD-YYYY Passages or Relevant Passages or Relevant Passages or Relevant Figures Appear  WO 02/096398 A2 12-05-2002 Esparma GmbH et al.  WO 02/096414 A1 12-05-2002 Serumwerk

Examiner Signature	T. A. Solo 6	Date Considered	1-23-06

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please ty	pe a plus sign inside this box +	P	TO/SB/08B(05/03)	Approved for use thr	ough 05/31/200	3, OMB	0651-	0031
				Application Number	10/764,676			
	INFORMATION DISC	Filing Date	January 26,	2004		<b>X</b>		
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Peter Rohne		44	: 7
				Group Art Unit	1615			
				Examiner Name		JUL	022	<b>00X</b> -73
Sheet	2	of	2	Attorney Docket Number	13183.0037	-		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
		European Search Report corresponding to 04001224.7-2107.		
Y0		JABLONKA, STANISLAW, ANDRZEJ LEDWOZYW, WOJCIECH KADZIOLKA, ANDRZEJ JABLONKA, AND ANDRZEJ NESTOROWICZ, "The Influence Of Ambroxol On Peroxidative Processes In Lung And Plasma In Dogs After Pulmonectomy," <u>Archivum Veterinarium Polonicum</u> , 1992, Pages 57-66, Volume 32, Number 1-2.		
		KOZHEVNIKOVA, E.V. AND L.M. ADZHIENKO, "Neuroprotective Activity Of Angiotensin-Converting Enzyme Inhibitors In Cerebral Ischemia," <u>Bulletin Of Experimental Biology And Medicine</u> , 1999, Pages 1122-1124, Volume 11.		
		PACKER, LESTER, HANS J. TRITSCHLER, AND KLAUS WESSEL, "Neuroprotection By The Metabolic Antioxidant α-Lipoic Acid," Free Radical Biology & Medicine, 1997, Pages 359-378, Volume 22, Numbers 1/2.		
		RAVATI, ALEXANDER, VERA JUNKER, MARIA KOUKLEI, BARBARA AHLEMEYER, CARSTEN CULMSEE, AND JOSEF KRIEGLSTEIN, "Enalapril And Moexipril Protect From Free Radical-Induced Neuronal Damage In Vitro And Reduce Ischemic Brain Injury In Mice And Rats," <u>European Journal Of Pharmacology</u> , 1999, Pages 21-33, Volume 373.		
		STOLL, S., A. ROSTOCK, R. BARTSCH, E. KORN, A. MEICHELBÖCK, AND W.E. MÜLLER, "The Potent Free Radical Scavenger & Lipoic Acid Improves Cognition In Rodents," <u>Annals New York Academy Of Sciences</u> , 1994, Pages 122-128.		
		WERNER, CHRISTIAN, WILLIAM E. HOFFMAN, EBERHARD KOCHS, SARA F. RABITO, AND DAVID J. MILETICH, "Captopril Improves Neurologic Outcome From Incomplete Cerebral Ischemia In Rats," Stroke, July 1991, Pages 910-914, Volume 22, Number 7.		
<del></del>				
	1			

Signature	· HI	5000	2 (0,	Considered	1-1306
Examiner	 1			Date	1 1 2 2 2 2 1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number. Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

BFLODOCS: 939527 v1 (K4XZ011.DOC)